A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-23 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
== Career and research == Tschöp obtained an M.D. from LMU Munich (1993), where he worked as a clinician (1994–1998) in neuroendocrinology before accepting a research fellowship at the Eli Lilly Discovery Research Laboratories (1999–2002) and leading a research team at the German Institute of Human Nutrition (Potsdam/Nuthetal 2002–2003). He was a Professor of Endocrinology and Diabetes at the Metabolic Diseases Institute of the University of Cincinnati (2003–2009), before being named the Arthur Russell Morgan Endowed Chair of Medicine, and Research Director of the Metabolism Center of Excellence for Diabetes and Obesity at the University of Cincinnati (2009–2011). He was Research Director of the Helmholtz Diabetes Center and Director of the Institute for Diabetes and Obesity at Helmholtz Zentrum München (2011–2018). Early in his career, Tschöp reported on the orexigenic, adipogenic, and metabolic effects of ghrelin and its secretory control by nutrients, which has had a major influence on human obesity and diabetes research. His corresponding publication in Nature is among today's most frequently cited metabolism research papers. It added a fundamental pathway to the current model of body weight and glucose control and established novel drug targets for metabolic diseases. Tschöp went on to further dissect gut-brain communication pathways, based on GI-hormone signaling and lessons from unraveling the molecular underpinnings of gastric bypass surgery.
==== Respiratory zone ==== The conducting zone of the respiratory tract ends at the terminal bronchioles when they branch into the respiratory bronchioles. This marks the beginning of the terminal respiratory unit called the acinus which includes the respiratory bronchioles, the alveolar ducts, alveolar sacs, and alveoli. An acinus measures up to 10 mm in diameter. A primary pulmonary lobule is the part of the lung distal to the respiratory bronchiole. Thus, it includes the alveolar ducts, sacs, and alveoli but not the respiratory bronchioles. The unit described as the secondary pulmonary lobule is the lobule most referred to as the pulmonary lobule or respiratory lobule. This lobule is a discrete unit that is the smallest component of the lung that can be seen without aid. The secondary pulmonary lobule is likely to be made up of between 30 and 50 primary lobules. The lobule is supplied by a terminal bronchiole that branches into respiratory bronchioles. The respiratory bronchioles supply the alveoli in each acinus and is accompanied by a pulmonary artery branch. Each lobule is enclosed by an interlobular septum. Each acinus is incompletely separated by an intralobular septum. The respiratory bronchiole gives rise to the alveolar ducts that lead to the alveolar sacs, which contain two or more alveoli. The walls of the alveoli are extremely thin allowing a fast rate of diffusion. The alveoli have interconnecting small air passages in their walls known as the pores of Kohn.
=== Housing === In 2026, Pritzker proposed the "Building Up Illinois Developments" (BUILD) plan for approval by the Illinois General Assembly to amend the fiscal year 2027 state budget, which involves amending the Illinois Municipal Code to relax zoning restrictions, permit greater volume of single-family housing units on lots, legalize the construction accessory dwelling units—granny flats, backyard cottages and above-garage apartments—on residential properties, and prohibit the enactment of minimum parking requirements for certain types of residential and mixed-use housing typically set by municipal governments, in order to spur housing construction and development to reduce costs and meet the state's housing supply needs. The plan also prevents building codes from prohibiting the construction of single-stair residential suites. On February 19, 2026, Representative Kam Buckner introduced the plan in the Illinois House of Representatives as HB5626. Accordingly, Pritzker's administration also authorized the Illinois Housing Development Authority to provide down-payment assistance through the IDHAccess Home program, calculated at 6% of the purchase price up to $15,000, for qualified, low- to middle-income homebuyers who do not own a home or have not owned one in the preceding three years, as well as veterans.
Sources: en.wikipedia.org
Ivermectin/albendazole is indicated for use in people aged five years of age or older, for the treatment of soil-transmitted helminth infections, caused by different types of intestinal parasitic worms, which are spread through soil contaminated by human feces in areas with poor sanitation. Among the worms responsible for these diseases are hookworms (Ancylostoma duodenale, Necator americanus), roundworms (Ascaris lumbricoides), whipworms (Trichuris trichiura) and a roundworm called Strongyloides stercoralis. Ivermectin/albendazole is also indicated for the treatment of microfilaraemia (the presence of worm larvae in the blood) in people with lymphatic filariasis. Lymphatic filariasis is a neglected tropical disease commonly known as elephantiasis, which impairs the lymphatic system and can lead to the abnormal enlargement of body parts, causing pain, severe disability and social stigma. Ivermectin/albendazole is indicated for the treatment of cases of lymphatic filariasis caused by Wuchereria bancrofti, a parasite which is responsible for 90% of cases worldwide.
Pakistan Horticulture Development & Export Board (PHDEC), an autonomous body under the administrative control of the Ministry of Commerce has been mandated with the development of the horticulture industry of Pakistan with a focus on exports. Its functions include the provision of improved marketing infrastructure like the establishment of agro-processing zones, cold chain system, processing plants for value-added products. The implementation arrangements are preferably under the public-private partnership (PPP) modality with a clear exit strategy. PHDEC envisions the vitalization of a dynamic and market-driven horticulture sector, which is resilient, sustainable and responsive to meet the challenges of globalization.
Dams – the Aztec in Tenochtitlan constructed great dams during the heyday of the Aztec Empire. Tenochtitlan, the capital of the Aztec empire, was first built on a small island that was located in the western section of Lake Texcoco in 1325 CE. The Aztec created various large artificial islands around the small island using a system that was similar to building the chinampas (floating gardens in the lake that was used to grow food for the cities' population). To provide drinking water to the cities' population of over a quarter of a million inhabitants, the Aztec built a system of dams that separated the salty waters of the lake from the rainwater that was accumulated during periods of heavy rains. The Aztec also used the dam to control the level of water in the lake and prevent their city from being flooded during times of heavy rains. To prevent flooding, the Aztec constructed an inner system of channels that helped to control the water level and held the level steady during flooding and periods of intense rains. Hernán Cortés, and the other Spanish conquistadors, destroyed these engineering marvels that the Aztec had developed during the previous 200 years. Dog breeds – Native American dogs believed to have been bred by indigenous Americans are the xochiocoyotl (coyote), xoloitzcuintli (known as xolo or Mexican hairless), chihuahua, Peruvian Hairless Dog, the Carolina Dog, Canadian Eskimo Dog, and the Alaskan Malamute.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.